Quarterly ResultMay 7, 2026, 04:21 PM
Assembly Biosciences Q1 Net Loss $9.1M; Advances Pipeline
AI Summary
Assembly Biosciences reported a net loss of $9.1 million, or $0.54 per share, for Q1 2026, compared to a net loss of $8.8 million, or $1.17 per share, in Q1 2025. Revenue from collaborative research with Gilead decreased to $8.2 million from $9.4 million year-over-year. The company highlighted significant pipeline progress, including the completion of Phase 1b studies for ABI-5366 and ABI-1179 for recurrent genital herpes, and chronic toxicology studies for ABI-6250 for chronic hepatitis delta virus, with Phase 2 initiation for ABI-6250 anticipated in Q4 2026. Cash, cash equivalents, and marketable securities stood at $226.6 million, projected to fund operations into 2028.
Key Highlights
- Net loss was $9.1 million, or $0.54 per share, for Q1 2026.
- Revenue from collaborative research was $8.2 million for Q1 2026.
- Cash, cash equivalents, and marketable securities totaled $226.6 million.
- Completed Phase 1b studies for ABI-5366 and ABI-1179 for genital herpes.
- Completed chronic toxicology studies for ABI-6250 for hepatitis delta virus.
- Anticipates Phase 2 initiation for ABI-6250 in Q4 2026.
- Will evaluate 40% U.S. cost-profit share for herpesvirus program by mid-2026.